Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892989) titled 'Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above' on Oct. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Condition:
Herpes Zoster
Intervention:
Biological: Recombinant Zoster Vaccine (CHO cell) SYS6052
Biological: Placebo: 0.9% sodium chloride injection
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 31, 2026
Target Sa...